Clinical trial
Alemtuzumab and Pentostatin In T-cell Neoplasms
NCT00453193 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00453193 |
|---|---|
| Title | Alemtuzumab and Pentostatin In T-cell Neoplasms |
| Official title | A Phase II Study of Alemtuzumab and Pentostatin In T-Cell Neoplasms |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Astex Pharmaceuticals, Inc. Industry Bayer |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Leukemia |
| Intervention type | Drug |
| Interventions | Pentostatin, Alemtuzumab |
| Enrollment | 26 |
| Start date | Sep 1, 2004 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Mar 28, 2007 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: